Home
HomeChat
Markets
AlertsCalendarScreenerCharts
Portfolio
WatchlistsPortfolioFiles
Account
Docs
Sign upJoinLog inLogin

AEON Biopharma, Inc. (AEON) stock profile

AEON Biopharma, Inc. is a biopharmaceutical company that focuses on developing botulinum toxins for the treatment of debilitating medical conditions. It also develops the 900 kDa botulinum toxin complex, ABP-450, for migraine, cervical dystonia, and gastroparesis. The company was formerly known as ALPHAEON Corporation and changed its name to AEON Biopharma, Inc. in December 2019. Incorporated in 2012, it is headquartered in Newport Beach, California.

Key facts

SymbolAEON
ExchangeAMEX
SectorHealthcare
IndustryBiotechnology
CEORobert Bancroft
Employees5
HeadquartersNewport Beach, CA, US
IPO2023-07-24
Websitewww.aeonbiopharma.com

Explore AEON on Vantafin

  • AEON Biopharma, Inc. Overview
  • AEON Biopharma, Inc. Financials
  • AEON Biopharma, Inc. News
  • AEON Biopharma, Inc. Events
  • AEON Biopharma, Inc. SEC filings
  • AEON Biopharma, Inc. Insider transactions

Frequently asked questions

What does AEON Biopharma, Inc. (AEON) do?
AEON Biopharma, Inc. is a biopharmaceutical company that focuses on developing botulinum toxins for the treatment of debilitating medical conditions. It also develops the 900 kDa botulinum toxin complex, ABP-450, for migraine, cervical dystonia, and gastroparesis. The company was formerly known as ALPHAEON Corporation and changed its name to AEON Biopharma, Inc. in December 2019. Incorporated in 2012, it is headquartered in Newport Beach, California.
Where is AEON stock listed?
AEON Biopharma, Inc. trades under the ticker AEON on AMEX.
How can I research AEON's financials and filings?
Vantafin provides AEON Biopharma, Inc.'s income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the AEON profile.